P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?

Por Self, S, Li, F, Corey, L, McElrath, J
Publicado em 2009

Cell free HIV-1 virus can infect inner and outer foreskin polarized explants

Por Lemos, MP, Perez, ML, Sanchez, J, Lama, J, Montano, S, McElrath, J
Publicado em 2012

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial

Por Fellay, J, Shianna, KV, Cirulli, ET, McElrath, J, Casimiro, DR, Geraghty, DE, Frahm, N, Goldstein, DB
Publicado em 2009

0A07-01. HIV-specific CD8(+ )T-cells of vaccinees exhibit proliferative and cytotoxic capacities comparable to those of progressors

Por Rood, JE, Migueles, SA, Berkley, AM, Compton, AA, Joshi, RP, Duerr, A, McElrath, J, Connors, M
Publicado em 2009

Most CD4+ T cells from human immunodeficiency virus-1 infected patients can undergo prolonged clonal expansion.

Por Langhoff, E, McElrath, J, Bos, H J, Pruett, J, Granelli-Piperno, A, Cohn, Z A, Steinman, R M
Publicado em 1989

Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients.

Por Kaplan, G., Nusrat, A., Sarno, E. N., Job, C. K., McElrath, J., Porto, J. A., Nathan, C. F., Cohn, Z. A.
Publicado em 1987

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting

Por Spearman, P, Tomaras, G, Montefiori, D, Huang, Y, Ahmed, H, Elizaga, M, Hural, J, McElrath, J, Ouedraogo, L, Pensiero, M, Butler, C, Kalams, S, Overton, ET, Barnett, S, Group, N
Publicado em 2012

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles

Por Goepfert, P, Elizaga, M, Montefiori, D, Hural, J, DeRosa, S, Tomaras, G, Seaton, K, Sato, A, Ouedraogo, L, Donastorg, Y, Cardinali, M, Lama, J, Baden, L, Keefer, M, McElrath, J, Kalams, S, Robinson, H
Publicado em 2012